Federation des caisses Desjardins du Quebec’s Recursion Pharmaceuticals RXRX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.3K	Buy	15,401 +3,310	+27%	+$12.8K	﹤0.01%	1878
2025 Q4	$49.5K	Sell	12,091 -1,035	-8%	-$5.13K	﹤0.01%	1819
2025 Q3	$64.1K	Sell	13,126 -19,965	-60%	-$105K	﹤0.01%	1749
2025 Q2	$167K	Sell	33,091 -12,000	-27%	-$59K	﹤0.01%	1264
2025 Q1	$239K	Buy	45,091 +2,000	+5%	+$14.6K	﹤0.01%	1144
2024 Q4	$291K	Buy	43,091 +591	+1%	+$3.97K	﹤0.01%	1074
2024 Q3	$280K	Sell	42,500 -3,500	-8%	-$25.1K	﹤0.01%	1076
2024 Q2	$345K	Hold	46,000	–	–	﹤0.01%	1018
2024 Q1	$459K	Buy	46,000 +1,900	+4%	+$21.2K	﹤0.01%	902
2023 Q4	$435K	Hold	44,100	–	–	﹤0.01%	805
2023 Q3	$337K	Buy	+44,100	New	+$440K	﹤0.01%	830

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's RXRX Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec increased its Recursion Pharmaceuticals (RXRX) stake by 27% in Q1 2026, buying an estimated $12.8K and bringing the position to 15,401 shares worth $47.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

Federation des caisses Desjardins du Quebec first reported a position in RXRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $459K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Federation des caisses Desjardins du Quebec held 15,401 shares of Recursion Pharmaceuticals worth $47.3K as of Q1 2026.
Federation des caisses Desjardins du Quebec bought 3,310 Recursion Pharmaceuticals shares in Q1 2026, an estimated $12.8K.
Recursion Pharmaceuticals made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #1878 holding.
Federation des caisses Desjardins du Quebec first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Federation des caisses Desjardins du Quebec's Recursion Pharmaceuticals position peaked at $459K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.